Anbio Biotechnology Class A Ordinary Shares (NNNN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Anbio Biotechnology Class A Ordinary Shares (NNNN) has a cash flow conversion efficiency ratio of 0.093x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.60 Million) by net assets ($17.19 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Anbio Biotechnology Class A Ordinary Shares - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Anbio Biotechnology Class A Ordinary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read NNNN liabilities breakdown for a breakdown of total debt and financial obligations.
Anbio Biotechnology Class A Ordinary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Anbio Biotechnology Class A Ordinary Shares ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Aavas Financiers Limited
NSE:AAVAS
|
-0.027x |
|
Darma Henwa Tbk
JK:DEWA
|
0.091x |
|
Pharming Group NV
NASDAQ:PHAR
|
0.133x |
|
Cadre Holdings Inc
NYSE:CDRE
|
0.067x |
|
Mitra Adiperkasa Tbk
JK:MAPI
|
0.124x |
|
Adtran Networks SE
F:ADV
|
0.047x |
|
Zhejiang Taihua New Material
SHG:603055
|
0.061x |
|
Shenzhen SEG Co Ltd
SHE:000058
|
0.110x |
Annual Cash Flow Conversion Efficiency for Anbio Biotechnology Class A Ordinary Shares (2021–2024)
The table below shows the annual cash flow conversion efficiency of Anbio Biotechnology Class A Ordinary Shares from 2021 to 2024. For the full company profile with market capitalisation and key ratios, see NNNN stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $17.19 Million | $2.08 Million | 0.121x | +99.61% |
| 2023-12-31 | $14.82 Million | $898.37K | 0.061x | -82.90% |
| 2022-12-31 | $12.55 Million | $4.45 Million | 0.355x | -78.50% |
| 2021-12-31 | $2.54 Million | $4.18 Million | 1.649x | -- |
About Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcript… Read more